SEARCH RESULT

Total Matching Records found : 380

India's proposal will help take the web out of U.S. control-Parminder Jeet Singh

-The Hindu Unnerved by the Indian stand, IT monopolies are propagating the myth that a multilateral governance structure will kill the decentralised, multi-stakeholder nature of the Internet and lead to ‘government control' Last year, in a statement to the U.N. General Assembly, India sought the creation of a U.N. Committee on Internet-Related Policies (CIRP) in order to democratise global Internet governance, which at present is either U.S.-controlled, or subject to the policies...

More »

Protests in US over high pricing of Novartis' anti-cancer drug Glivec-Divya Rajagopal

Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...

More »

The government needs to think out of the box to help pharma grow while keeping medicines affordable-Ramesh Adige

Having watched from the ringside for many years now, I have no doubt in advising that the steering wheel must be firmly grasped by the government and direction given to policies that should be stable for at least the medium term. This is crucial for the growth of Indian pharma, a $20-billion industry growing at an average of 12% considering both domestic and export arenas. Price control: The biggest and most...

More »

Bayer to challenge Cipla’s decision to cut price of cancer drug

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...

More »

NPCIL told to publicize safety analysis reports-Anuja & Jacob P Koshy

Reluctance to make reports public could erode public confidence in government’s decisions, says CIC The Central Information Commission (CIC) has directed India’s nuclear power plant operator to publicize safety analysis reports of the Kudankulam atomic power plant within a month. In a contentious two-year dispute between environmentalists and the nuclear power establishment, the apex information commission, in an order on its website, has said that the reluctance to make the reports public...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close